Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Science

• Publication date

  2015-10-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/science.aad0095PMID 26359337PMCID PMC5054517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

  2015cited by this paper
• Genomic Classification of Cutaneous Melanoma.

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Biomarkers in cancer immunotherapy.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Mutant MHC class II epitopes drive therapeutic immune responses to cancer

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

  2015cited by this paper
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

  2015cited by this paper
• Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

  2014cited by this paper
• Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens

  2014cited by this paper
• Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

  2014cited by this paper
• Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

  2014cited by this paper
• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

  2014cited by this paper
• Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

  2013cited by this paper
• Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine

  2013cited by this paper
• Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

  2013cited by this paper
• Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation

  2013cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Integrative Genomics Viewer

  2011cited by this paper
• ContEst: estimating cross-contamination of human samples in next-generation sequencing data

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence

  2007cited by this paper
• GenePattern 2.0

  2006cited by this paper
• High Frequency of Melanoma-Associated Antigen or HLA Class I Loss Does Not Correlate with Survival in Primary Melanoma

  2004cited by this paper
• Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.

  1999cited by this paper

• Towards the tumor microenvironment scoring methods for immune checkpoint inhibitor response

  2026cites this paper
• Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma

  2026cites this paper
• Harnessing Anoikis-Related Gene Signatures for Immunotherapy Precision: A Machine Learning-Driven Predictive and Prognostic Model.

  2026cites this paper
• Decoding the tumor microenvironment remodeling orchestrated by CLEC3B+ inflammatory cancer-associated fibroblasts in lung adenocarcinoma immunotherapy: elucidation from pan-cancer spatially single-cell transcriptomics landscape

  2026cites this paper
• Mutation-informed gene pairs to predict melanoma metastasis

  2026cites this paper
• Association of copy number alterations with the immune transcriptomic landscape in cancer

  2026cites this paper
• Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure.

  2026cites this paper
• Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy

  2026cites this paper
• SUMOylation of SND1 drives mature miRNA degradation and tumor progression.

  2026cites this paper
• Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer

  2026cites this paper
• Melanoma Beyond the Microscope in the Era of AI and Integrated Diagnostics

  2026cites this paper
• Assays to examine lymphocyte invasion.

  2026cites this paper
• S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity

  2026cites this paper
• CDK10 suppresses nucleic acid sensors-mediated antitumor immunity

  2026cites this paper
• The broad spectrum of cancer and immunotherapy: achievements and limitations

  2026cites this paper
• NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes

  2026cites this paper
• Transcriptional activation of LINGO1 facilitates proliferation and immune escape in colorectal cancer.

  2026cites this paper
• Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors.

  2026cites this paper
• Tumor immune organoids in immunotherapy resistance and drug screening.

  2026cites this paper
• Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer

  2026cites this paper
• Hypoxia-Driven Immune Escape in Clear Cell Renal Cell Carcinoma: A Prognostic Model and Dual-Functional Biomarker PLOD2 for Immunotherapy Stratification

  2026cites this paper
• Harnessing machine learning-driven multiomics integration: deciphering programmed cell death networks for prognostication and immunotherapy prediction in lung adenocarcinoma

  2026cites this paper
• NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis

  2026cites this paper
• FKBP10 promotes M2 polarization of macrophage via MEK/ERK/CXCL8 axis and facilitates tumor progression in clear cell renal cell carcinoma

  2026cites this paper
• Artificial intelligence–enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation

  2026cites this paper
• A serum metabolite-based machine learning model predicts response to neoadjuvant immunotherapy in mismatch repair-deficient colorectal cancer.

  2026cites this paper
• Cross-talk of m6A methylation modification and the tumor microenvironment composition in esophageal cancer

  2025cites this paper
• CCT3 as a promising diagnostic and prognostic biomarker in HCC.

  2025cites this paper
• Immunogenicity of neoantigens: From CAR-T cell to various vaccines.

  2025cites this paper
• Single-cell and multi-omics analysis reveals the role of stem cells in prognosis and immunotherapy of lung adenocarcinoma patients

  2025cites this paper
• LncRNA antigens - a novel resource to improve immunotherapy efficacy predictions in melanoma

  2025cites this paper
• NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer

  2025cites this paper
• CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models

  2025cites this paper
• Current trends in single‐cell RNA sequencing applications in diabetes mellitus

  2025cites this paper
• Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China

  2025cites this paper
• Elucidating DNA Damage-Dependent Immune System Activation

  2025cites this paper
• Toward precision oncology in LUAD: a prognostic model using single-cell sequencing and WGCNA based on a disulfidptosis relative gene signature

  2025cites this paper
• STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity

  2025cites this paper
• Chaperonin containing TCP1 subunit 5 as a novel pan-cancer prognostic biomarker for tumor stemness and immunotherapy response: insights from multi-omics data, integrated machine learning, and experimental validation

  2025cites this paper
• Comparative Transcriptomics Study of Curcumin and Conventional Therapies in Translocation, Clear Cell, and Papillary Renal Cell Carcinoma Subtypes

  2025cites this paper
• The Critical Role of APOE+ Macrophages in the Immune Microenvironment and Prognosis of Lung Adenocarcinoma

  2025cites this paper
• Selective USP7 inhibition synergizes with MEK1/2 inhibitor to enhance immune responses and potentiate anti-PD-1 therapy in NRAS mutant melanoma.

  2025cites this paper
• Genetic and transcriptional insights into immune checkpoint blockade response and survival: lessons from melanoma and beyond

  2025cites this paper
• Investigation of tumor mutation burden using the comprehensive genomic profiling data of vulvar and vaginal malignant tumors: an observational study using C-CAT database

  2025cites this paper
• Unravelling Cancer Immunity: Coagulation.Sig and BIRC2 as Predictive Immunotherapeutic Architects

  2025cites this paper
• CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

  2025cites this paper
• NetLnc: A Network-Based Computational Framework to Identify Immune Checkpoint-Related lncRNAs for Immunotherapy Response in Melanoma

  2025cites this paper
• Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

  2025cites this paper
• The Immunogenic Tumor-Specific Neoantigen Database (ITSNdb): A Tool for Comprehensive Performance Evaluation of Neoantigen Immunogenicity Predictors.

  2025cites this paper
• Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer

  2025cites this paper
• Pan-cancer analysis of ALK mutation and its association with tumor immunogenicity and the efficacy of immune checkpoint blockade.

  2025cites this paper
• Integrated Single-Cell and Bulk RNA Sequencing Analysis Identifies a Regulated Cell Death-Related Gene Signature for Predicting Prognosis and Therapeutic Responses in Cutaneous Melanoma.

  2025cites this paper
• Comprehensive analysis of single-cell and bulk RNA sequencing data reveals an EGFR signature for predicting immunotherapy response and prognosis in pan-cancer

  2025cites this paper
• Integrating multi-omics data to optimize immunotherapy in endometrial cancer: a comprehensive study

  2025cites this paper
• Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

  2025cites this paper
• Isolation of mitochondrial mutation-specific T cell receptors.

  2025cites this paper
• Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology

  2025cites this paper
• Expression signatures with specificity for type I and II IFN response and relevance for autoimmune diseases and cancer

  2025cites this paper
• Integrative analysis of multi-omics data and gut microbiota composition reveals prognostic subtypes and predicts immunotherapy response in colorectal cancer using machine learning

  2025cites this paper
• In-depth patient-specific analysis of tumor heterogeneity in melanoma brain metastasis: Insights from spatial transcriptomics and multi-region bulk sequencing

  2025cites this paper
• LARS2 DNA methylation predicts the prognosis in colon cancer

  2025cites this paper
• Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy

  2025cites this paper
• Increased fatty acid delivery by tumor endothelium promotes metastatic outgrowth

  2025cites this paper
• Impact of radiation therapy on the immunological tumor microenvironment.

  2025cites this paper
• Explainable machine learning identifies features and thresholds predictive of immunotherapy response

  2025cites this paper
• Stratification by Mutational Landscape Reveals Differential Immune Infiltration and Predicts the Recurrence and Clinical Outcome of Cervical Cancer

  2025cites this paper
• Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma

  2025cites this paper
• Pediatric gliomas immunity challenges and immunotherapy advances.

  2025cites this paper
• Neoantigens: new hope for cancer therapy

  2025cites this paper
• First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.

  2025cites this paper
• A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Avelumab

  2025cites this paper
• Bioinformatics analysis across pan-cancer and experimental validation in hepatocellular carcinoma revealed the oncogenic role of SF3B6

  2025cites this paper
• Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma

  2025cites this paper
• Systemic Therapy for Melanoma: What Surgeons Need to Know.

  2025cites this paper
• Classification of renal cell carcinoma based on immunogenomic profiling

  2025cites this paper
• Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts

  2025cites this paper
• Targeting pyroptosis reverses KIAA1199-mediated immunotherapy resistance in colorectal cancer

  2025cites this paper
• Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients

  2025cites this paper
• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial

  2025cites this paper
• Research review of the mechanism and clinical application prospects of tertiary lymphoid structures in the immune micro-environment of gastrointestinal tumors

  2025cites this paper
• Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

  2025cites this paper
• Activating antiviral immune responses potentiates immune checkpoint inhibition in glioblastoma models

  2025cites this paper
• BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma

  2025cites this paper
• AMPK-dependent Parkin activation suppresses macrophage antigen presentation to promote tumor progression

  2025cites this paper
• A tumor-infiltrating B lymphocytes -related index based on machine-learning predicts prognosis and immunotherapy response in lung adenocarcinoma

  2025cites this paper
• Mutational signature-based biomarker to predict the response of immune checkpoint inhibitors therapy in cancers.

  2025cites this paper
• Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.

  2025cites this paper
• Abscopal Effects and Immunomodulation in Skin Cancer Therapy

  2025cites this paper
• A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci

  2025cites this paper
• Pancreatic cancer subtyping - the keystone of precision treatment

  2025cites this paper
• Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma

  2025cites this paper
• A Rare Case of Xeroderma Pigmentosum: Nivolumab Treatment for Three Cutaneous Malignancies with Clinical and Metabolic Imaging Correlation

  2025cites this paper
• Single-cell technology: the key to an improved understanding of the human endometrium in health and disease.

  2025cites this paper
• ProgModule: A novel computational framework to identify mutation driver modules for predicting cancer prognosis and immunotherapy response

  2025cites this paper
• Promising Treatment Strategy for Primary Malignant Melanoma of the Esophagus by Radical Esophagectomy and Nivolumab as Adjuvant Therapy: A Case Report

  2025cites this paper
• Of Context, Quality, and Complexity: Fine-combing Tumor Mutation Burden in Immunotherapy Treated Cancers.

  2025cites this paper
• Integration of Single‐Cell RNA Sequencing Data and Bulk Sequencing Data to Characterise the CD8+ T‐Cell Exhaustion Mediated Immune Microenvironment in CRC

  2025cites this paper
• Deciphering the Immunomodulatory Function of GSN + Inflammatory Cancer‐Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan‐Cancer Single‐Cell Landscape and Spatial Transcriptomics Analysis

  2025cites this paper
• Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers

  2025cites this paper